Epic Sciences Inc, a developer of novel diagnostics to personalise and advance the treatment and management of cancer, disclosed on Monday the addition of Richard J. Wenstrup, MD as its chief medical officer.
In the medical department, Dr Wenstrup will lead the company's clinical development, oversee its regulatory and medical affairs strategies as well as be responsible for advancing its clinical research and product development pipeline.
Dr Wenstrup has served in a variety of clinical leadership roles managing life science companies over the past 25 years. He was the chief medical officer for Oxford Immunotec Inc and Myriad Genetics before that.
Previously, Dr Wenstrup was a tenured professor of paediatrics in human genetics at Cincinnati Children's Hospital Medical Center as well as in biomedical engineering at the University of Cincinnati.
Also, Dr Wenstrup was the founding director of the Molecular Diagnostics Laboratory at Cincinnati Children's Hospital as well as a co-founder of Assurex Health Inc.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval